6499.TWO Medeon Biodesign
- Market cap
- TWD 6.87B
- P/E
- -
- P/B
- 5.64x
- ROE
- -40.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6499.TWO undervalued?
Graham numberThe Graham number of Medeon Biodesign cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medeon Biodesign fundamental analysis
No fundamental analysis for Medeon Biodesign yet.
Medeon Biodesign stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, …
Full company profileMedeon Biodesign financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Medeon Biodesign annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 165M | 674M | 454M | 654M | 69.0M | 298M | 196M | 293M | 419M | 442M |
| Gross Profit | 45.8M | 481M | 186M | 355M | 28.6M | 187M | 14.4M | 83.4M | 58.8M | 58.5M |
| Operating Income | -274M | 175M | -257M | -97.0M | -496M | -488M | -839M | -872M | -722M | -541M |
| EBITDA | -230M | 266M | -172M | -26.1M | -454M | -370M | -1.13B | -754M | -609M | -442M |
| Net Income | -248M | 257M | -262M | -193M | 2.08B | -434M | -1.20B | -806M | -668M | -493M |
| EPS | -3.93 | 4.07 | -3.58 | -2.65 | 28 | -4.95 | -13 | -8.74 | -6.89 | -5.09 |
| Balance Sheet | ||||||||||
| Total Assets | 1.64B | 1.95B | 2.52B | 3.31B | 4.36B | 4.04B | 2.75B | 1.88B | 1.78B | 1.55B |
| Total Liabilities | 105M | 149M | 268M | 667M | 176M | 376M | 376M | 342M | 243M | 282M |
| Shareholders' Equity | 1.34B | 1.64B | 2.00B | 2.05B | 4.13B | 3.60B | 2.32B | 1.52B | 1.48B | 1.23B |
| Cash & Short-term Investments | 285M | 328M | 472M | 1.13B | 735M | 484M | 1.24B | 513M | 521M | 452M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -311M | 322M | -242M | -151M | -293M | -461M | -755M | -833M | -629M | -467M |
| Capital Expenditure | 149M | 51.1M | 48.9M | 20.2M | 8.32M | 141M | 55.8M | 74.8M | 16.9M | 9.37M |
| Free Cash Flow | -460M | 268M | -293M | -172M | -302M | -602M | -811M | -907M | -646M | -477M |
| Ratios | ||||||||||
| ROE | -18.4% | 15.7% | -13.1% | -9.4% | 50.3% | -12.1% | -51.9% | -53.0% | -45.3% | -40.1% |
| ROA | -15.1% | 13.2% | -10.4% | -5.8% | 47.6% | -10.7% | -43.8% | -42.9% | -37.5% | -31.8% |
| Net Profit Margin | -150.2% | 38.1% | -57.7% | -29.5% | 3,013.8% | -145.4% | -613.8% | -275.1% | -159.3% | -111.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Medeon Biodesign dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 23, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | TWD 43.8M | 0.48 | - |
| 2022 | TWD 73.0M | 0.83 | - |
| 2021 | TWD 73.0M | 1.00 | 3.5% |
| 2020 | TWD 73.0M | 1.00 | - |
| 2019 | TWD 73.0M | 1.00 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1049.9929:1000 on Aug 23, 2023.
Who owns Medeon Biodesign
- Insiders 39.13%
- Institutions 0.00%
- Public & others 60.87%
- Shares outstanding 96.9M
- Free float 55.5M
Medeon Biodesign company profile
- Company name
- Medeon Biodesign
- Ticker
- 6499.TWO
- ISIN
- TW0006499007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 116, HouGang Street, Taipei, Taiwan, 11170
- Phone
- 886 2 2881 6686
- Website
- medeonbiodesign.com
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.
Medeon Biodesign management
5- Dr. Yue-Teh Jang Ph.D.Chairman of the Board & GM
- Dr. Jenny ChenVP of Finance & Business Analysis, Head of Corporate Governance and CFO
- Ms. Tori LinSenior Manager of Finance & Business Analysis and Accounting Officer
- Ms. Greta ChangExecutive Vice President
- Mr. Albert WengVP of Products Development